This clinical trial is focused on studying psoriatic arthritis, a condition that causes joint pain and swelling in people who have psoriasis, a skin disease. The study aims to understand how reducing the use of certain medications can help maintain minimal disease activity, which means keeping the symptoms under control. The medications being studied include a variety of treatments that help manage the immune system, such as methotrexate disodium, abatacept (also known as Orencia), certolizumab pegol (known as Cimzia), secukinumab (known as Cosentyx), risankizumab (known as Skyrizi), tofacitinib (known as Xeljanz), upadacitinib (known as Rinvoq), apremilast (known as Otezla), ixekizumab (known as Taltz), guselkumab (known as Tremfya), ustekinumab (known as Stelara), golimumab (known as Simponi), etanercept, adalimumab, infliximab, leflunomide, sulfasalazine, and prednisolone. Some participants may receive a placebo, which is a substance with no active medication.
The purpose of the study is to evaluate how far these medications can be reduced without causing a return of symptoms. Participants will be randomly assigned to different treatment groups, and the study will last for up to 24 months. During this time, the participants’ health will be closely monitored to ensure that their condition remains stable. The study will involve regular check-ups to assess the activity of the disease and the overall health and quality of life of the participants.
Throughout the study, participants will receive either the medication or a placebo, and their progress will be tracked to see if they can maintain minimal disease activity. The study will help determine the best approach to managing psoriatic arthritis with the least amount of medication necessary, aiming to improve the quality of life for those affected by this condition.
Germany 
Italy 
